SYMANSIS
CELL SIGNALING SCIENCE

Product Data Sheet

Compound Name	CEP-33779
N-(3-(4-methylpiperazin-1-yl)phenyl)-8-(4-(methylsulfonyl) phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-amine	Catalog Number SY-CEP-33779

Structure



CAS Number
[1346168-57-7]

Molecular Weight
462.57

Empirical Formula:
$C_{24}H_{26}N_6O_2S$

Purity: >95%

HPLC >99.3% @ 245nm

NMR confirmed sequence

ES-MS: 463.2 [M+1]

Mode of Action:	Kinase inhibitor
Predominant Target(s):	JAK2
Published Activity:	CEP-33779 is a highly selective, orally active inhibitor for JAK2 with IC50 of 1.8nM in enzyme and 61nM in cell, comparing to the inhibition for JAK3 with IC50 of 150nM.
Development stage:	Research
Storage & Handling:	Store dry, unopened vial ambient, protected from light for up to 3 months or unopened vial, protected from light at -70ºC for up to 1 year. Liquefy material in 100% ACS grade DMSO. Store liquefied material at -80ºC, in aliquots, protected from light, for up to 1 month. Prevent multiple freeze-thaw cycles. Product ships ambient.

SYMANSIS LTD, PO Box 2117, 26 Kennels Road, Timaru 7974, New Zealand, Phone: +64-3-687-4498

References		

K. L. Stump, L. D. Lu, P. Dobrzanski, C. Serdikoff, D. E. Gingrich, B. J. Dugan, T. S. Angeles, M. S. Albom, M. A. Ator, B. D. Dorsey, B. A. Ruggeri, M. M. Seavey (2011) "A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. "*Arthritis Res. Ther*. **13(2)**, R68.

Matthew M Seavey, Lily D Lu, Kristine L Stump, Nate H Wallace, William Hockeimer, Teresa M O'Kane, Bruce Ruggeri, and Pawel Dobrzanski (2012) "Therapeutic Efficacy of CEP-33779, a Novel Selective JAK2 Inhibitor, in a Mouse Model of Colitis-induced Colorectal Cancer" *Mol Cancer Ther*. 2012 Apr;**11(4):**984-93